Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients
Abstract
Purpose: This study examines the role of {sup 18}F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) in the implementation of involved-node radiation therapy (INRT) in patients treated for clinical stages (CS) I/II supradiaphragmatic Hodgkin lymphoma (HL). Methods and Material: Patients with untreated CS I/II HL enrolled in the randomized EORTC/LYSA/FIL Intergroup H10 trial and participating in a real-time prospective quality assurance program were prospectively included in this study. Data were electronically obtained from 18 French cancer centers. All patients underwent APET-computed tomography (PET-CT) and a post-chemotherapy planning CT scanning. The pre-chemotherapy gross tumor volume (GTV) and the postchemotherapy clinical target volume (CTV) were first delineated on CT only by the radiation oncologist. The planning PET was then co-registered, and the delineated volumes were jointly analyzed by the radiation oncologist and the nuclear medicine physician. Lymph nodes undetected on CT but FDG-avid were recorded, and the previously determined GTV and CTV were modified according to FDG-PET results. Results: From March 2007 to February 2010, 135 patients were included in the study. PET-CT identified at least 1 additional FDG-avid lymph node in 95 of 135 patients (70.4%; 95% confidence interval [CI]: 61.9%-77.9%) and 1 additional lymph node area in 55 of 135 patients (40.7%; 95%more »
- Authors:
-
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif (France)
- Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif (France)
- Department of Medicine, Institut Gustave Roussy, Villejuif (France)
- Department of Imaging, Institut Gustave Roussy, Villejuif (France)
- Department of Medical Physics, Institut Gustave Roussy, Villejuif (France)
- Department of Information Technology, Institut Gustave Roussy, Villejuif (France)
- Department of Imaging, Institut Curie R. Huguenin Hospital, Saint-Cloud (France)
- Publication Date:
- OSTI Identifier:
- 22420392
- Resource Type:
- Journal Article
- Journal Name:
- International Journal of Radiation Oncology, Biology and Physics
- Additional Journal Information:
- Journal Volume: 89; Journal Issue: 5; Other Information: Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 62 RADIOLOGY AND NUCLEAR MEDICINE; CAT SCANNING; CHEMOTHERAPY; FLUORINE 18; FLUORODEOXYGLUCOSE; HODGKINS DISEASE; LYMPH NODES; MEDICAL PERSONNEL; PATIENTS; PLANNING; POSITRON COMPUTED TOMOGRAPHY; QUALITY ASSURANCE; RADIOTHERAPY
Citation Formats
Girinsky, Théodore, Aupérin, Anne, Ribrag, Vincent, Elleuch, Manel, Fermé, Christophe, Bonniaud, Guillaume, Ruelle, Claude, Alberini, Jean-Louis, Celebic, Aljosa, and Edeline, Véronique. Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients. United States: N. p., 2014.
Web. doi:10.1016/J.IJROBP.2014.04.026.
Girinsky, Théodore, Aupérin, Anne, Ribrag, Vincent, Elleuch, Manel, Fermé, Christophe, Bonniaud, Guillaume, Ruelle, Claude, Alberini, Jean-Louis, Celebic, Aljosa, & Edeline, Véronique. Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients. United States. https://doi.org/10.1016/J.IJROBP.2014.04.026
Girinsky, Théodore, Aupérin, Anne, Ribrag, Vincent, Elleuch, Manel, Fermé, Christophe, Bonniaud, Guillaume, Ruelle, Claude, Alberini, Jean-Louis, Celebic, Aljosa, and Edeline, Véronique. 2014.
"Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients". United States. https://doi.org/10.1016/J.IJROBP.2014.04.026.
@article{osti_22420392,
title = {Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients},
author = {Girinsky, Théodore and Aupérin, Anne and Ribrag, Vincent and Elleuch, Manel and Fermé, Christophe and Bonniaud, Guillaume and Ruelle, Claude and Alberini, Jean-Louis and Celebic, Aljosa and Edeline, Véronique},
abstractNote = {Purpose: This study examines the role of {sup 18}F-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) in the implementation of involved-node radiation therapy (INRT) in patients treated for clinical stages (CS) I/II supradiaphragmatic Hodgkin lymphoma (HL). Methods and Material: Patients with untreated CS I/II HL enrolled in the randomized EORTC/LYSA/FIL Intergroup H10 trial and participating in a real-time prospective quality assurance program were prospectively included in this study. Data were electronically obtained from 18 French cancer centers. All patients underwent APET-computed tomography (PET-CT) and a post-chemotherapy planning CT scanning. The pre-chemotherapy gross tumor volume (GTV) and the postchemotherapy clinical target volume (CTV) were first delineated on CT only by the radiation oncologist. The planning PET was then co-registered, and the delineated volumes were jointly analyzed by the radiation oncologist and the nuclear medicine physician. Lymph nodes undetected on CT but FDG-avid were recorded, and the previously determined GTV and CTV were modified according to FDG-PET results. Results: From March 2007 to February 2010, 135 patients were included in the study. PET-CT identified at least 1 additional FDG-avid lymph node in 95 of 135 patients (70.4%; 95% confidence interval [CI]: 61.9%-77.9%) and 1 additional lymph node area in 55 of 135 patients (40.7%; 95% CI: 32.4%-49.5%). The mean increases in the GTV and CTV were 8.8% and 7.1%, respectively. The systematic addition of PET to CT led to a CTV increase in 60% of the patients. Conclusions: Pre-chemotherapy FDG-PET leads to significantly better INRT delineation without necessarily increasing radiation volumes.},
doi = {10.1016/J.IJROBP.2014.04.026},
url = {https://www.osti.gov/biblio/22420392},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 89,
place = {United States},
year = {Fri Aug 01 00:00:00 EDT 2014},
month = {Fri Aug 01 00:00:00 EDT 2014}
}